BridgeBio Pharma (BBIO) Opinions on $300 Million Royalty Financing Deal
6/7 19:00
Recent discussions on X about BridgeBio Pharma (BBIO) have centered around the company's announcement of a $300 million royalty financing deal for its drug acoramidis, known as BEYONTTRA in Europe. Many users have highlighted this as a significant move to bolster the company’s fi...